$508 Million is the total value of VR Adviser, LLC's 27 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 51.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TCDA | Buy | Tricida Inc | $69,039,000 | +86.9% | 7,132,079 | +58.7% | 13.60% | +127.1% |
| ACRS | Aclaris Therapeutics Inc | $63,713,000 | -19.0% | 4,563,962 | 0.0% | 12.55% | -1.6% | |
| RLMD | Relmada Therapeutics Inc | $43,109,000 | -29.6% | 2,270,072 | 0.0% | 8.49% | -14.5% | |
| TVTX | Sell | Travere Therapeutics Inc | $41,460,000 | -19.4% | 1,711,102 | -14.2% | 8.16% | -2.0% |
| COGT | Buy | Cogent Biosciences Inc | $36,424,000 | +346.6% | 4,038,117 | +270.9% | 7.17% | +443.0% |
| GHRS | Buy | GH Research PLCord sh | $31,792,000 | -15.3% | 3,185,573 | +55.3% | 6.26% | +3.0% |
| TIL | Sell | Instil Bio Inc | $27,709,000 | -62.5% | 5,997,657 | -12.6% | 5.46% | -54.4% |
| CLDX | Celldex Therapeutics Inc | $23,324,000 | -20.8% | 865,116 | 0.0% | 4.59% | -3.8% | |
| VRDN | Viridian Therapeutics Inc | $21,438,000 | -37.4% | 1,852,919 | 0.0% | 4.22% | -23.9% | |
| VTGN | Buy | VistaGen Therapeutics Inc | $18,214,000 | -8.5% | 20,697,286 | +29.0% | 3.59% | +11.3% |
| Marinus Pharmaceuticals Inc | $15,279,000 | -48.2% | 3,156,803 | 0.0% | 3.01% | -37.1% | ||
| Sell | Aadi Bioscience Inc | $14,458,000 | -44.3% | 1,173,518 | -23.3% | 2.85% | -32.3% | |
| INZY | New | Inozyme Pharma Inc | $12,927,000 | – | 2,709,987 | +100.0% | 2.55% | – |
| AKUS | New | Akouos Inc | $12,509,000 | – | 2,667,119 | +100.0% | 2.46% | – |
| LianBiospons adr | $11,617,000 | -41.8% | 5,378,341 | 0.0% | 2.29% | -29.2% | ||
| AVTE | Buy | Aerovate Therapeutics Inc | $9,228,000 | +233.3% | 590,408 | +290.9% | 1.82% | +304.7% |
| TRVI | New | Trevi Therapeutics Inc | $8,571,000 | – | 3,050,022 | +100.0% | 1.69% | – |
| KDNY | Sell | Chinook Therapeutics Inc | $8,563,000 | -59.2% | 489,618 | -61.9% | 1.69% | -50.5% |
| ANNX | New | Annexon Inc | $7,270,000 | – | 1,928,477 | +100.0% | 1.43% | – |
| SVRA | Buy | Savara Inc | $6,259,000 | +150.8% | 4,117,530 | +116.1% | 1.23% | +205.2% |
| LYRA | New | Lyra Therapeutics Inc | $5,222,000 | – | 924,170 | +100.0% | 1.03% | – |
| PRVB | Provention Bio Inc | $4,475,000 | -45.4% | 1,118,653 | 0.0% | 0.88% | -33.6% | |
| ALT | Sell | Altimmune Inc | $4,321,000 | -6.6% | 369,306 | -51.4% | 0.85% | +13.5% |
| LIFE | aTyr Pharma Inc | $3,959,000 | -47.1% | 1,398,889 | 0.0% | 0.78% | -35.6% | |
| AFMD | Affimed NV | $3,957,000 | -36.6% | 1,428,571 | 0.0% | 0.78% | -22.9% | |
| New | Rallybio Corp | $2,027,000 | – | 268,532 | +100.0% | 0.40% | – | |
| XENE | New | Xenon Pharmaceuticals Inc | $913,000 | – | 30,000 | +100.0% | 0.18% | – |
| Exit | Astria Therapeutics Inc | $0 | – | -538,999 | -100.0% | -0.59% | – | |
| CNTA | Exit | Centessa Pharmaceuticals PLCspons adr | $0 | – | -411,361 | -100.0% | -0.60% | – |
| SRRA | Exit | Sierra Oncology Inc | $0 | – | -162,479 | -100.0% | -0.84% | – |
| GRPH | Exit | Graphite Bio Inc | $0 | – | -1,612,617 | -100.0% | -1.33% | – |
| Exit | Nuvalent Inc | $0 | – | -803,951 | -100.0% | -1.81% | – | |
| EIGR | Exit | Eiger BioPharmaceuticals Inc | $0 | – | -1,469,767 | -100.0% | -1.98% | – |
| ATHA | Exit | Athira Pharma Inc | $0 | – | -1,000,000 | -100.0% | -2.19% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.